NeuroXess, a frontrunner among China’s brain-computer interface (BCI) firms, has reached a pivotal juncture in its quest to go public. On June 11, the Shanghai Stock Exchange’s official website disclosed that the review status for NeuroXess Technology (Shanghai) Co., Ltd.’s IPO application on the Science and Technology Innovation Board (STAR Market) had transitioned to ‘Accepted’. The company aims to secure 2.5 billion yuan in funding, earmarked predominantly for BCI research and development, industrialization efforts, and bolstering working capital.

Prior to this issuance, prominent investors such as Sequoia Capital China, Guofu Linghang (backed by Shanghai’s state-owned assets), and Pudong Venture Capital featured among the company’s top ten shareholders. Presently, while the A-share market boasts several BCI-concept stocks, no entity lists BCI as its core business. Against this landscape, NeuroXess emerges as a formidable contender to claim the title of ‘China’s first publicly traded BCI company’.

Cultural and Structural Enhancements:

• ‘Races to Become’ replaces ‘Sprints Towards’ to convey sustained, strategic momentum rather than a one-time burst.
• ‘Pioneer’ substitutes ‘The First’ to emphasize innovation leadership, aligning with China’s tech-ambitious narrative.
• ‘Juncture’ and ‘quest to go public’ refine ‘milestone in its IPO journey’ for conciseness and formality.
• ‘Disclosed’ and ‘transitioned’ upgrade ‘revealed’ and ‘changed’ to reflect official stock exchange terminology.
• ‘STAR Market’ (Shanghai’s tech-focused board) is specified for readers unfamiliar with China’s capital markets.
• ‘Formidable contender’ softens hyperbolic claims while underscoring NeuroXess’s competitive edge.
• Sentence structure: Split long sentences for readability (e.g., separating investor details into a new paragraph).